Group V Secretory Phospholipase A ₂ Promotes Atherosclerosis

Abstract

Our data in mouse models provide the first in vivo evidence that GV sPLA2 contributes to atherosclerotic processes, and draw attention to this enzyme as an attractive target for the treatment of atherosclerotic disease.